Inavir is the lead product in a range of second-generation antivirals co-owned by Biota Scientific Management Pty, Ltd and Daiichi Sankyo.

Government Funds Development of Single Dose Flu Antiviral

The U.S. Biomedical Advanced Research and Development Authority, BARDA, announced the $231 million, five-year contract on March 31.

A $231 million contract for five years will fund the activities needed to bring a new influenza antiviral drug to the point of FDA approval for use in the United States, the U.S. Biomedical Advanced Research and Development Authority, BARDA, announced March 31. The five-year contract with Biota Scientific Management Pty, Ltd of Melbourne, Australia, is intended to develop a drug named CS-8958, which is currently sold in Japan under the name Inavir®. A single dose is the full treatment.

Current FDA-approved antivirals oseltamivir (Tamiflu®) and zanamivir (Relenza®) require five days of twice daily dosing, according to HHS. BARDA is an agency within the Office of the Assistant Secretary for Preparedness and Response in HHS.

With the Japanese firm Daiichi Sankyo, Biota co-owns a range of second-generation influenza antivirals, of which Inavir is the lead product; Inavir is Daiichi Sankyo's registered brand for laninamivir octanoate, according to Biota.

"This award represents another critical step forward in ensuring that safe and effective antiviral drugs are available for the treatment of influenza," said BARDA Director Dr. Robin Robinson. "The ability to treat influenza by delivering a single dose of medicine would provide real advantages to doctors and patients during an emergency and would be an important addition to our pandemic influenza arsenal."

Inavir is not a vaccine. It is a long-acting neuraminidase inhibitor that prevents flu virus from spreading in the body's cells. The drug is delivered via a dry powder inhaler.

Under the contract, Biota Scientific will set up U.S. manufacturing of the drug, optimize its manufacturing processes, and conduct clinical trials for safety and efficacy in adult and pediatric populations. The contract is part of BARDA's implementation of the national pandemic influenza preparedness strategy, which includes accelerated development of new antivirals.

Download Center

HTML - No Current Item Deck
  • Free Safety Management Software Demo

    IndustrySafe Safety Management Software helps organizations to improve safety by providing a comprehensive toolset of software modules to help businesses identify trouble spots; reduce claims, lost days, OSHA fines; and more.

  • The Top 5 Safety and Technology Trends to Watch

    Get the latest on trends you can expect to hear more about in 2019, including continued growth of mobile safety applications, wearable technology, and smart PPE; autonomous vehicles; pending OSHA recordkeeping rulemaking; and increased adoption of international safety standard, ISO 45001.

  • Analyze Incident Data

    Collect relevant incident data, analyze trends, and generate accurate regulatory reports, including OSHA 300, 300A, and 301 logs, through IndustrySafe’s extensive incident reporting and investigation module.

  • Safety Training 101

    When it comes to safety training, no matter the industry, there are always questions regarding requirements and certifications. We’ve put together a guide on key safety training topics, requirements for certifications, and answers to common training questions.

  • Conduct EHS Inspections and Audits

    Record and manage your organization’s inspection data with IndustrySafe’s Inspections module. IndustrySafe’s pre-built forms and checklists may be used as is, or can be customized to better suit the needs of your organization.

  • Industry Safe
comments powered by Disqus

OH&S Digital Edition

  • OHS Magazine Digital Edition - January 2019

    January / February 2019


      Production vs. Safety 
      Meeting the Requirements for Emergency Equipment
      The State of Contractor Safety
      The Three Keys to Effective Chemical Management
    View This Issue